LATS1 and cancer: On the one hand, core components of the Hippo pathway MST1/2 and LATS1/2 were downregulated, and this downregulation was involved in the inactivation of Hippo signaling (46, 47); on the other hand, upregulation of the Hippo pathway transcription coactivators YAP and TAZ further exacerbated inactivation of the Hippo signaling, promoting the development and progression of cancers (48).